Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2009. The report serves as a notification to the market regarding the company's total voting rights and capital structure as of December 31, 2008, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital (as of Dec 31, 2008): 5,661,316,237 Ordinary shares of 25p each.
- Treasury Shares: 474,194,158 Ordinary shares.
- Total Voting Rights: 5,187,122,079.
Material Changes
The filing text does not provide comparative data for prior periods to determine material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a statutory notification intended to provide shareholders with the correct denominator for calculating disclosure thresholds under the Financial Services Authority's rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,187,122,079) when calculating ownership thresholds for regulatory disclosures.
- Note that the reported share capital excludes 474,194,158 shares held in Treasury.
- Confirm that this filing does not contain financial performance results for the period.